Most recently, scholars in China reported early evidence that plasma Gal-3 levels of Huntington’s disease patients correlate with disease severity, and that suppression of Gal-3 suppresses inflammation, and restores neuronal DARPP32 levels, improving motor dysfunction, and increasing survival in mice affected by the disease. This evidence concerns the gene PPP1R1B and juvenile Huntington disease.